<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00330317</url>
  </required_header>
  <id_info>
    <org_study_id>CFEM345EGB07</org_study_id>
    <nct_id>NCT00330317</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Hormone Therapy With Letrozole in Postmenopausal Women With Breast Cancer</brief_title>
  <official_title>Neoadjuvant Hormone Therapy for Postmenopausal Women With HR+ Primary Breast Cancer: A Multi-center Study to Determine the Optimum Length of Treatment With Letrozole on Tumour Regression to Permit Breast Conserving Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the safety and efficacy of neoadjuvant hormone therapy&#xD;
      with letrozole in postmenopausal women with estrogen- and/or progesterone-receptor positive&#xD;
      primary breast cancer on tumour regression to permit breast conserving surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">November 16, 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Optimum length of treatment with letrozole (2.5 mg daily) preoperatively, on tumour measured by clinical examination and breast ultrasound</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in tumour volume every 2 months throughout the study</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate in line with the Response Evaluation Criteria in Solid Tumors criteria</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term (5-year) local recurrence rate</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of the treatment prior to surgery</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>letrozole</intervention_name>
    <description>2.5mg letrozole once-daily</description>
    <arm_group_label>Letrozole</arm_group_label>
    <other_name>Femara, FEM345</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Postmenopausal women able to comply with the protocol requirements with confirmed&#xD;
             primary invasive breast cancer whose tumours are estrogen-and/or progesterone-receptor&#xD;
             positive&#xD;
&#xD;
          2. Clinical stage T2 or &gt;T2 tumours which in the investigators' opinion would not be&#xD;
             eligible for breast-conserving surgery. The nodal status will be evaluated by&#xD;
             palpation and/or ultrasound.&#xD;
&#xD;
          3. Postmenopausal status defined by one of the following:&#xD;
&#xD;
               -  Women with an intact uterus AND&#xD;
&#xD;
                    -  ≥ 55 years of age, OR&#xD;
&#xD;
                    -  &lt; 55 years of age without menses for the last 5 years, OR&#xD;
&#xD;
                    -  &lt; 55 years of age and have not had menses for at least the last 12 months&#xD;
                       (but have had menses in the last 5 years) and have postmenopausal levels of&#xD;
                       follicle-stimulating hormone.&#xD;
&#xD;
               -  Women without an intact uterus AND&#xD;
&#xD;
                    -  ≥ 55 years of age, OR&#xD;
&#xD;
                    -  &lt; 55 years of age and postmenopausal levels of follicle-stimulating hormone&#xD;
&#xD;
               -  Both ovaries removed (prior to the diagnosis of breast cancer).&#xD;
&#xD;
          4. Tumour measurable by clinical examination, mammography and ultrasound&#xD;
&#xD;
          5. Adequate bone marrow function as shown by:&#xD;
&#xD;
               -  WBC ≥ 3.5 x 10^9/L&#xD;
&#xD;
               -  ANC ≥ 1.5 x 10^9/L&#xD;
&#xD;
               -  Platelets ≥ LLN&#xD;
&#xD;
               -  Hb &gt; 10 g/dL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Multifocal disease (cancer that starts in several different sites)&#xD;
&#xD;
          2. Patients with bilateral breast tumours.&#xD;
&#xD;
          3. Patients who are eligible for breast conserving surgery.&#xD;
&#xD;
          4. Evidence of inflammatory breast cancer or distant metastasis.&#xD;
&#xD;
          5. Simultaneous anti-cancer treatments such as chemotherapy, immunotherapy/biological&#xD;
             response modifiers, endocrine therapy (including steroids), bisphosphonate therapy and&#xD;
             radiotherapy. NOTE: Bisphosphonate therapy for osteoporosis is NOT excluded, and can&#xD;
             be continued. Patients who have received hormone replacement therapy will NOT be&#xD;
             excluded if it is discontinued at least 2 weeks before starting the study.&#xD;
&#xD;
        The following additional treatments are NOT allowed during the treatment phase of the&#xD;
        study:&#xD;
&#xD;
          -  Any other anti-cancer therapy&#xD;
&#xD;
          -  Hormone replacement therapy.&#xD;
&#xD;
          -  Estrogen cream (including any intra-vaginal preparation).&#xD;
&#xD;
          -  Steroids other than creams or inhalers.&#xD;
&#xD;
          -  Megestrol acetate for the treatment of hot flushes.&#xD;
&#xD;
          -  Radiation therapy.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmeceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bournemouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brighton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Crewe</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dundee</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>East Sussex</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Epping</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Farnworth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gateshead</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hants</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Luton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poole</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Leonards on Sea</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>West Smithfield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Carpenter R, Doughty JC, Cordiner C, Moss N, Gandhi A, Wilson C, Andrews C, Ellis G, Gui G, Skene AI. Optimum duration of neoadjuvant letrozole to permit breast conserving surgery. Breast Cancer Res Treat. 2014 Apr;144(3):569-76. doi: 10.1007/s10549-014-2835-8. Epub 2014 Feb 23.</citation>
    <PMID>24562823</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>May 24, 2006</study_first_submitted>
  <study_first_submitted_qc>May 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2006</study_first_posted>
  <last_update_submitted>February 3, 2017</last_update_submitted>
  <last_update_submitted_qc>February 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Letrozole</keyword>
  <keyword>Breast Conserving Surgery</keyword>
  <keyword>NeoAdjuvant</keyword>
  <keyword>Early Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

